Anavex Life Sciences Corp (AVXL)

[crescentmotor]

Just as we think Anavex is starting to execute, today's PR is a reminder of how poorly the company handles its PR.

AVXL's communications efforts have a compelling history of missteps and I have criticized the company for years in this area. One thing the Street abhors and punished stock prices for is uncertainty. When shorts control your company's stock price and are short 25% of the float, the company has to issue clear and succinct PRs to avoid giving the shorts ammunition. AVXL today effectively turned a stand up triple into a foul ball. This is a misstep 100% on them.

How did such a clinical success story "drug effective beyond 4 years" turn into a "Now we need a phase 3 trial but we don't have a phase 3 plan yet" in front of the 500 CEOs.

No one on this board, including The Shade Thrower--Investor2014, has a clue as to what today's confusing disclosure really means. Elon Musk would be at loss to accurately interpret the meeting. What is becoming a lot clearer, after the recent stock price drop of 19%, is that the JPM conference may well turn out to be a non-event in terms of a meaningful positive impact on AVXL's stock price. Shame on AVXL for this sloppiness.